Clinical trials
Limited Stage Small Cell Lung Cancer clinical trials
Below are recruiting limited stage small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 460 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06496048RecruitingPhase 3
Testing lurbinectedin for small cell lung cancer that has returned
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
Jilin CityAges 18 years+ - NCT07559786RecruitingPhase 2
Adebrelimab after chemo-radiation for limited-stage small cell lung cancer
This trial tests whether the drug adebrelimab (a type of immunotherapy) can help prevent your lung cancer from coming back after you finish chemotherapy and radiation. It is for people with limited-stage small cell lung cancer (cancer found only in one lung and nearby lymph nodes) that did not grow during initial treatment.
Zhengzhou, HenanAges 18–75 - NCT07566052RecruitingPhase 3
Comparing a new KRAS drug to docetaxel for advanced lung cancer
This trial tests a new pill (setidegrasib) against a standard chemo drug (docetaxel) for people with a specific type of advanced lung cancer that has a KRAS G12D mutation. The goal is to see which treatment works better.
Glendale, CaliforniaAges 18 years+ - NCT06467617RecruitingPhase 2
Immunotherapy and chemo before and after lung cancer surgery
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07565532Recruiting
Small Cell Lung Cancer Treatment Study With Radiation
This study follows patients with small cell lung cancer who receive radiation therapy combined with other treatments. Researchers will track how well the treatment works and how patients respond over time to help improve future care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06734182RecruitingPhase 2
Targeted therapy plus chemo before surgery for HER2-mutant lung cancer
This study tests a combination of two targeted drugs (envafolimab and disitamab vedotin) plus chemotherapy (carboplatin) given before surgery for lung cancer that has a HER2 mutation. The goal is to see if this can shrink the tumor and improve outcomes.
GuangzhouAges 18–75 - NCT06735391RecruitingPhase 3
JMT101 plus osimertinib vs osimertinib for EGFR-mutant lung cancer
This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.
GuangzhouAges 18 years+ - NCT07554339RecruitingPhase 3
Calderasib and Durvalumab for Advanced Lung Cancer After Chemotherapy
This trial tests a combination of two drugs—calderasib (a targeted therapy) and durvalumab (an immunotherapy)—for people with a specific type of advanced lung cancer that has a KRAS G12C mutation. The goal is to prevent the cancer from coming back after standard chemotherapy and radiation treatment.
Lisle, IllinoisAges 18 years+ - NCT06739928RecruitingPhase 2
Irinotecan liposome with immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of irinotecan liposome (a chemotherapy) or etoposide with adebrelimab (an immunotherapy) and carboplatin for people with extensive-stage small cell lung cancer who haven't had prior treatment. It aims to see if these combinations are safe and effective.
Guangzhou, GuangzhouAges 18–70 - NCT07545954RecruitingPhase 1
DSP-0390 plus Atezolizumab for Small Cell Lung Cancer
This trial tests a new drug called DSP-0390 combined with atezolizumab (an immunotherapy) in patients with small cell lung cancer who have already completed initial chemotherapy treatment. The goal is to see if this combination can help prevent the cancer from coming back or growing.
St Louis, MissouriAges 18 years+ - NCT07548060RecruitingPhase 2
New drug combination for advanced lung cancer after prior treatments
This trial tests two newer drugs (sacituzumab tirumotecan and furmonertinib) together for patients with advanced non-squamous lung cancer whose tumors have specific genetic mutations and have stopped responding to earlier EGFR-targeted drugs and chemotherapy. The goal is to find out if this combination can help patients whose cancer has progressed.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06749860RecruitingPhase 2
Targeted drug combo for HER2-positive advanced lung cancer
This trial tests a combination of three drugs (Disitamab Vedotin, Tislelizumab, and Bevacizumab) for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene or protein. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT07531095RecruitingPhase 1
Combination drug trial for small cell lung cancer
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
Goodyear, ArizonaAges 18–99 - NCT07528274RecruitingPhase 2
Microwave ablation with immunotherapy for advanced lung cancer
This trial tests combining microwave ablation (heat treatment of tumors) with two drugs—tislelizumab (an immune-boosting drug) and docetaxel (chemotherapy)—for patients with advanced non-small cell lung cancer whose disease progressed after initial immunotherapy. The goal is to see if this combination can slow or shrink tumors better than standard treatment alone.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06480864Recruiting
Study of adebelimumab and apatinib for extensive stage small cell lung cancer maintenance
This trial tests whether adding two targeted therapies (adebelimumab, an immunotherapy, and apatinib, a drug that blocks blood vessel growth) after initial chemotherapy can help keep extensive stage small cell lung cancer under control. It is for people who have not yet had systemic treatment for their cancer and are in good enough health to try this maintenance approach.
Shenyang, LiaoningAges 18 years+ - NCT07513376RecruitingPhase 3
Adjuvant vaccine plus immunotherapy for high-risk early lung cancer
This trial tests whether giving a personalized cancer vaccine (Intismeran) with or without an immunotherapy drug (pembrolizumab) after lung cancer surgery can help prevent the cancer from coming back in patients with early-stage, high-risk non-small cell lung cancer.
Sacramento, CaliforniaAges 18 years+ - NCT07508852RecruitingPhase 1/Phase 2
PET scan for small cell lung cancer diagnosis
This study uses a special PET scan (68Ga-PFD3) to take pictures of small cell lung cancer tumors. The goal is to see if this scan can help doctors better diagnose and evaluate the cancer, which may guide treatment decisions.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06769971RecruitingPhase 2
Ivonescimab and cadonilimab plus chemo for extensive-stage small cell lung cancer
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
Chengdu, SichuanAges 18–75 - NCT06581419RecruitingPhase 1/Phase 2
Testing IAP0971 in advanced solid tumors and lung cancer
This trial tests a new drug called IAP0971 for people with advanced solid tumors or a specific type of lung cancer. It may help if your cancer has not responded to other treatments or if you have PD-L1-positive lung cancer that hasn't been treated yet.
Beijing, Beijing MunicipalityAges 18–75 - NCT07489391Recruiting
Exercise during radiation for lung cancer
This trial tests whether adding a structured exercise program during radiation and chemotherapy helps people with locally advanced lung cancer. It aims to improve physical function and quality of life.
Barcelona, CataloniaAges 18 years+ - NCT06667167RecruitingPhase 2
First-line Keytruda + chemo then Keytruda + Trodelvy for SCLC
This trial tests a two-step treatment for extensive-stage small cell lung cancer: first, chemotherapy combined with Keytruda (an immunotherapy), followed by Keytruda plus Trodelvy (another targeted drug). The goal is to see if this combination helps people live longer and keeps the cancer under control.
Jerusalem, IsraelAges 18–99 - NCT07472517RecruitingPhase 3
Obrixtamig plus standard therapy for advanced small cell lung cancer
This trial tests whether adding a new drug, obrixtamig, to the usual first treatment for extensive-stage small cell lung cancer can help people live longer or slow the cancer's growth. The usual treatment is a combination of atezolizumab, carboplatin, and etoposide.
Mobile, AlabamaAges 18 years+ - NCT07473128RecruitingPhase 3
Trilaciclib to prevent low blood cell counts in limited-stage small cell lung cancer
This trial tests whether taking trilaciclib alongside standard chemotherapy can help prevent low blood cell counts (myelosuppression) in people with limited-stage small cell lung cancer. It may help you stay stronger during treatment.
Oakland, CaliforniaAges 18 years+ - NCT06780826Recruiting
Atezolizumab plus chemo for extensive-stage small cell lung cancer
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
ShanghaiAges 18 years+
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for limited stage small cell lung cancer?
- Yes. Clin2 currently lists 460 recruiting limited stage small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a limited stage small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a limited stage small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Small Cell Lung Cancer Extensive Stage
- Non-small Cell Lung Cancer Stage III
- Non Small Cell Lung Cancer
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- Stage IIIA Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Squamous Cell Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.